PharmaEssentia Corporation PharmaEssentia Corporation

PharmaEssentia Corporation

6446

Clasificación en acciones #1443
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Precio por acción
$36.73
Última sincronización: 2026-10-20
Capitalización bursátil
$15.19B
Cambio (1 día)
-1.70%
Cambio (1 año)
141.45%
País
TW
Comercio PharmaEssentia Corporation (6446)

Categoría

Healthcare
Historial de desdoblamientos de acciones de PharmaEssentia Corporation (6446)
La acción PharmaEssentia Corporation (símbolo: 6446) tuvo un total de 2 desdoblamientos.
El desdoblamiento más reciente ocurrió el Jul 09, 2026.
Una acción 6446 comprada antes de Sep 11, 2025 equivaldría hoy a 1.229881 acciones 6446.
Lista de desdoblamientos de acciones
Año Desdoblamiento Multiplicador Multiplicador acumulado
2026-07-09 1109:1000 x1.109 x1.229881
2025-09-11 1109:1000 x1.109 x1.109
Desdoblamientos de acciones de empresas similares o competidoras
Empresa Número de desdoblamientos de acciones Multiplicador acumulado País
0 -
DE
0 -
DE
0 -
JP
0 -
CH
5 x119
IN